Compare Eli Lilly And Co (LLY) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nuwellis Inc — how do they compare? Eli Lilly And Co trades at $1,214.46 (market cap $1.08T), while Nuwellis Inc trades at $1.41 (market cap $542.80K). The key difference: Eli Lilly And Co is far larger — about 1989683.1× Nuwellis Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| LLY | NUWE | |
|---|---|---|
Market Cap | $1.08T | $542.80K |
Sector | Health | Technology |
52-Week High | $1.24K | $220.50 |
52-Week Low | $639.43 | $1.42 |
Enterprise Value | $1.13T | -$1.27M |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.
Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
